PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
27 February 2009 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENT TO
COMMERCIALIZE DERMATOLOGICAL PRODUCTS WITH DALOS BIOPHARMA
(Charlottesville, VA, 27 February 2009) – PluroGen Therapeutics, Inc. today announced the signing of a
Letter of Intent with Dalos BioPharma for the companies to develop and commercialize new products
based on PluroGen’s and Dalos’ proprietary technologies. Initial products targeted will be anti-infective
topical gels, spray disinfectants, facial cleansers, body washes, liquid or gel hand cleansers and shampoos.
PluroGen President & CEO Neal G. Koller, in announcing this new commercial partnership, commented that
“this Letter of Intent creates another important new sales opportunity for our products and technologies,
in this case an additional personal skin care market opportunity with unique, differentiating technology
provided by Dalos. This is another, very strategic, step forward in our plan to expand the utility and
opportunity for PluroGen’s technologies. It further confirms the value of our products and technologies,
and, of our significant multiple market opportunities.”
Gary Pekoe, President & CEO of Dalos Pharma commented “we are very pleased to establish a
relationship with PluroGen. PluroGen technologies provides a unique opportunity for the delivery of Dalos’
phytoceutical products. The combination of the technologies provides new, differentiated and superior
products for both companies’ markets. This also expands the potential uses of Dalos’ products. We are
looking forward to a long and beneficial relationship between our companies.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel™ and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel™
Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™ / ActiviGel™ technology is currently in routine use
at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in
two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About Dalos BioPharma
Dalos BioPharma is a topical skin care company specializing in developing products for bacterial and viral
infections of the skin, as well as inflammatory skin conditions. Dalos’ products are naturally-occurring
botanical products, derived from a proprietary single source. Dalos’ “platform technology” is a single-
sourced substance that has multiple uses / actions across a broad range of diseases. The substance is a
very complex mix of plant phytochemicals that need to remain intact in order for their natural synergy to
work. A phytochemical is a non-nutrient botanical substance that has disease-fighting ability.
Dalos has launched its first two products, PoxiDerm™ and MersaDerm™. PoxiDerm™ is indicated for the
topical relief of molluscum contagiosum, a pox-virus based viral infection of the skin. MersaDerm™ is
indicated for the relief of MRSA (methicillin-resistant Staph aureus) and other topical bacterial infections of
the skin.
For more information about Dalos BioPharma, visit the company’s web site at www.dalosbio.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and Dalos BioPharma website is not incorporated herein by
reference or otherwise.
© PluroGen Therapeutics, Inc. 2009
President & CEO
27 February 2009 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENT TO
COMMERCIALIZE DERMATOLOGICAL PRODUCTS WITH DALOS BIOPHARMA
(Charlottesville, VA, 27 February 2009) – PluroGen Therapeutics, Inc. today announced the signing of a
Letter of Intent with Dalos BioPharma for the companies to develop and commercialize new products
based on PluroGen’s and Dalos’ proprietary technologies. Initial products targeted will be anti-infective
topical gels, spray disinfectants, facial cleansers, body washes, liquid or gel hand cleansers and shampoos.
PluroGen President & CEO Neal G. Koller, in announcing this new commercial partnership, commented that
“this Letter of Intent creates another important new sales opportunity for our products and technologies,
in this case an additional personal skin care market opportunity with unique, differentiating technology
provided by Dalos. This is another, very strategic, step forward in our plan to expand the utility and
opportunity for PluroGen’s technologies. It further confirms the value of our products and technologies,
and, of our significant multiple market opportunities.”
Gary Pekoe, President & CEO of Dalos Pharma commented “we are very pleased to establish a
relationship with PluroGen. PluroGen technologies provides a unique opportunity for the delivery of Dalos’
phytoceutical products. The combination of the technologies provides new, differentiated and superior
products for both companies’ markets. This also expands the potential uses of Dalos’ products. We are
looking forward to a long and beneficial relationship between our companies.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel™ and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel™
Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™ / ActiviGel™ technology is currently in routine use
at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in
two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About Dalos BioPharma
Dalos BioPharma is a topical skin care company specializing in developing products for bacterial and viral
infections of the skin, as well as inflammatory skin conditions. Dalos’ products are naturally-occurring
botanical products, derived from a proprietary single source. Dalos’ “platform technology” is a single-
sourced substance that has multiple uses / actions across a broad range of diseases. The substance is a
very complex mix of plant phytochemicals that need to remain intact in order for their natural synergy to
work. A phytochemical is a non-nutrient botanical substance that has disease-fighting ability.
Dalos has launched its first two products, PoxiDerm™ and MersaDerm™. PoxiDerm™ is indicated for the
topical relief of molluscum contagiosum, a pox-virus based viral infection of the skin. MersaDerm™ is
indicated for the relief of MRSA (methicillin-resistant Staph aureus) and other topical bacterial infections of
the skin.
For more information about Dalos BioPharma, visit the company’s web site at www.dalosbio.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and Dalos BioPharma website is not incorporated herein by
reference or otherwise.
© PluroGen Therapeutics, Inc. 2009